オハイオにおける脂肪肝の臨床試験
オハイオ内の拠点で、脂肪肝に関する15件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Springboro
- GSK Investigational Site, Westlake
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Cleveland Clinic, Cleveland
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Akron Gastro Research, Akron
- Dayton Gastroenterology - Beavercreek, Beavercreek
- Clinical Research Institute of Ohio - Brooklyn, Brooklyn
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07165028Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第2相
5歳〜16歳 · 全性別 · 2026/09/22更新 · NCT06133101A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Akron
- Akero Clinical Study Site, Springboro
- Akero Clinical Study Site, Westlake
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/21更新 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Akron
- GSK Investigational Site, Springboro
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/17更新 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Akron Gastro Research, Akron
- Digestive Specialists, Dayton
- DSI Research, Springboro
- 他1件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/09更新 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Akron
- 89bio Clinical Study Site, Dayton
- 89bio Clinical Study Site, Dayton
- 他4件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Akron
- 89bio Clinical Study Site, Cincinnati
- 89bio Clinical Study Site, Cleveland
- 他5件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/03更新 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Cleveland
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/08/03更新 · NCT06613698Fibrosis Lessens After Metabolic Surgery
- Cleveland Clinic, Cleveland
被験者募集中第4相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/07/31更新 · NCT06374875A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Akron
- GSK Investigational Site, Springboro
- GSK Investigational Site, Westlake
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/27更新 · NCT07221227Milk Thistle Clinical Trial in Pediatric NAFLD
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第2相
9歳〜22歳 · 全性別 · 2026/01/27更新 · NCT06477146Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD
- southwoods imaging (Northeastern Ohio Radiology Research and Education Fund ), Boardman
被験者募集中
18歳以上 · 全性別 · 2025/09/25更新 · NCT07192159Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Ohio Clinical Trials, Columbus
被験者募集中観察研究
18歳〜75歳 · 全性別 · 2025/08/14更新 · NCT07122700ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。